RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints

Inclusion Criteria: * • Subjects with hand OA having suffered from transient inflammatory attacks of the interphalangeal finger joints characteristic for what has been termed 'inflammatory' or 'erosive' hand OA. * Subjects with hand OA showing inflammatory signs, either clinically or ultrasonographically, of the interphalangeal finger joints. * Subjects with hand OA in which at least 1 interphalangeal finger joint has the typical appearance on the X-rays of a 'J' or 'E' phase joint as defined by the criteria mentioned above. * Subjects with hand OA where at least 1 interphalangeal finger joint in the 'J' or 'E' phase presents a palpable swelling. Exclusion Criteria: * Patients with known hypersensitivities to mammalian-derived drug preparations. * Patients with clinically significant hypersensitivity to any of the components of Prolia. * Current and/or Prior treatment with any investigational agent within 90 days, or five half-lives of the product, whichever is longer. * Previous administration of denosumab from clinical trials or others (e.g. commercial use). * Vitamin D deficiency \[25(OH) vitamin D level \< 20 ng/mL (\< 49.9 nmol/L)\]. Possibility of replenishment and re-screening. * Subjects with current hypo- or hypercalcemia (normal serum calcium levels: 8.5-10.5 mg/dl or 2.12-2.62 mmol/L). * Patients currently under bisphosphonate (BP) treatment or any use of oral BPs within 12 months of study enrollment or intravenous BPs or strontium ranelate within 5 years…